Projekt: Role and potential therapeutic use of interleukin-22+ Innate Lymphoid cells in colitis

MD / PhD Chiara Romagnani (Teilprojekt B14)
Deutsches Rheuma-Forschungszentrum (DRFZ) Berlin
Charitéplatz 1, 10117  Berlin

AnsprechpartnerIn: MD / PhD Chiara Romagnani

Inflammatory bowel disease (IBD) is mediated by dysfunctional immunity. IL-22 is an IL-10 family cytokine member specifically targeting mucosal tissues and was shown to be protective in pre-clinical models of IBD. IL-22 is mainly produced by Innate Lymphoid cell (ILC) subsets, which have been recently identified both in human and mouse mucosa associated tissues, especially in the gut. The group has recently identified the signals resulting in ILC selective expression of either protective cytokines such as IL-22 or pro-inflammatory ones such as TNF. In this project, we will test whether other stimuli, such as engagement of Notch receptors cann also regulate IL-22 production in Innate Lymphoid cells and how that may impact IBD in vivo.


Hier finden Sie die Internetseiten des Promotionsbüros der Charité.